Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy
暂无分享,去创建一个
Jeffrey E. Lee | M. Katz | J. Wilks | Michael P. Kim | N. Ikoma | J. Soliz | T. Newhook | C. Tzeng | L. Prakash | E. Arvide | J. Maxwell | M. Bruno | W. Dewhurst | B. B. Speer | Shannon Hancher-Hodges | Jose Soliz
[1] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[2] V. Valero,et al. The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy. , 2019, Annals of surgery.
[3] Jeffrey E. Lee,et al. Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[4] Jeffrey E. Lee,et al. Risk‐stratified clinical pathways decrease the duration of hospitalization and costs of perioperative care after pancreatectomy , 2018, Surgery.
[5] J. Lacy,et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. , 2018, Journal of the National Cancer Institute.
[6] E. Sloan,et al. Perioperative events influence cancer recurrence risk after surgery , 2018, Nature Reviews Clinical Oncology.
[7] Bin Huang,et al. Effect of complications on oncologic outcomes after pancreaticoduodenectomy for pancreatic cancer. , 2017, The Journal of surgical research.
[8] J. Cata. Can the Perioperative Anesthesia Care of Patients With Cancer Affect Their Long-term Oncological Outcomes? , 2017, Anesthesia and analgesia.
[9] M. Hollmann,et al. Perioperative Anesthesia Care and Tumor Progression , 2017, Anesthesia and analgesia.
[10] D. Gouma,et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After , 2017, Surgery.
[11] L. Schwartz,et al. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. , 2016, JAMA surgery.
[12] B. Erickson,et al. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. , 2015, Journal of gastrointestinal oncology.
[13] P. Karanicolas,et al. The impact of peri-operative blood transfusions on post-pancreatectomy short-term outcomes: an analysis from the American College of Surgeons National Surgical Quality Improvement Program. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[14] A. Ejaz,et al. Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis , 2015, Annals of Surgical Oncology.
[15] A. Ejaz,et al. Impact of Blood Transfusions and Transfusion Practices on Long-Term Outcome Following Hepatopancreaticobiliary Surgery , 2015, Journal of Gastrointestinal Surgery.
[16] Jeffrey E. Lee,et al. Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy , 2015, Annals of Surgical Oncology.
[17] A. Parikh,et al. Perioperative Blood Transfusion Is Associated with Decreased Survival in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: a Multi-institutional Study , 2014, Journal of Gastrointestinal Surgery.
[18] N. Blumberg,et al. Transfusion immunomodulation from a clinical perspective: an update , 2013, Expert review of hematology.
[19] D. Sessler,et al. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. , 2013, British journal of anaesthesia.
[20] J. Vauthey,et al. Postoperative Complications and Oncologic Outcomes after Resection of Colorectal Liver Metastases: The Importance of Staying on Track , 2013, Annals of Surgical Oncology.
[21] A. Stenzinger,et al. Postoperative Complications Deteriorate Long-Term Outcome in Pancreatic Cancer Patients , 2012, Annals of Surgical Oncology.
[22] W. Hawkins,et al. The Accordion Severity Grading System of Surgical Complications , 2009, Annals of surgery.
[23] Jeffrey E. Lee,et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. , 2008, Journal of the American College of Surgeons.
[24] R. Parks,et al. Perioperative transfusion for pancreaticoduodenectomy and its impact on prognosis in resected pancreatic ductal adenocarcinoma. , 2007, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[25] D. Gouma,et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). , 2007, Surgery.
[26] E. Vamvakas,et al. Transfusion-related immunomodulation (TRIM): an update. , 2007, Blood reviews.
[27] C. Ko,et al. Multimodality therapy for pancreatic cancer in the U.S. , 2007, Cancer.
[28] J. Yu,et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer , 2006, Journal of Gastrointestinal Surgery.
[29] E. Mascha,et al. Can Anesthetic Technique for Primary Breast Cancer Surgery Affect Recurrence or Metastasis? , 2006, Anesthesiology.
[30] P. Christiansen,et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery , 1992, The British journal of surgery.
[31] P. Tartter,et al. EFFECT OF BLOOD TRANSFUSIONS ON COLONIC MALIGNANCY RECURRENCE RATE , 1982, The Lancet.
[32] Jeffrey E. Lee,et al. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience , 2016, Journal of Gastrointestinal Surgery.
[33] Jeffrey E. Lee,et al. Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival , 2013, Journal of Gastrointestinal Surgery.